Navigation Links
Glenmark's Consolidated Revenue Increases by 16.56% to Rs. 14630.06 Mn for Q2 FY 13-14
Date:10/31/2013

mp; MD - Glenmark.  Although the operating environment continues to remain challenging in emerging markets, we are reasonably confident of continuing on the same growth trajectory."

For the six month ended Sep 30, 2013, Glenmark's consolidated revenue was at Rs. 27008.88 Mn [USD 457.46 Mn] as against Rs. 22955.98 Mn [USD 418.52 Mn], an increase of 17.66 %. Revenue from the generics business was at Rs. 13374.19 Mn (USD 226.52 Mn), as against Rs. 11118.97 Mn (USD 202.71 Mn), a growth of 20.28 %. The Speciality formulation business revenue (excluding out-licensing revenue) was Rs. 13516.59. Mn (USD 228.93 Mn) as against Rs. 11837.01 (USD  215.80 Mn) for the corresponding previous six month period, recording a growth of 14.19%.

Specialty Business:

Sales for the formulation business in India for the second quarter ended Sep 30, 2013, was at Rs. 4176.80 Mn [USD 67.51Mn] as against Rs. 3440.27 Mn [USD 62.47 Mn] in the previous corresponding quarter, recording a growth of 21.41% For the second quarter, revenue from Africa, Asia and CIS region was as against Rs.1735.91Mn [USD 27.74Mn] as against Rs. 1941.00 Mn [USD 35.26 Mn] for the previous corresponding quarter. Glenmark's revenue from its Latin American and Caribbean operations was at Rs. 966.00Mn [USD 15.50Mn] for the second quarter ended Sep 30, 2013 as against Rs. 990.54Mn [USD 18.00Mn] for the previous corresponding period.

Generics Business:

Glenmark Generics Inc., U.S.A. registered revenue from sale of finished dosage formulations was Rs. 5578.60Mn (USD 90.09Mn) for the quarter ended Sep 30, 2013against revenue of 4307.21 Mn (USD 78.17 Mn) for the previous corresponding quarter, recording an increase of 29.52%. The European business posted revenues of Rs. 517.20 Mn (USD8.30Mn) for the quarter ended Sep 30, 2013against revenue of R
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CryoLife Third Quarter 2013 Revenues Increase 8 Percent to a Record $36.3 Million
2. Neogen reports 18% revenue increase
3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
4. BioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013
5. Sales Momentum Helps Companies Drive Revenue by Getting Major Account Sales Strategy Right
6. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
7. SPO Returns to Revenue Generation
8. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
9. Medical Marijuana Inc., Corporate Update- Significant Revenue and Net Income Growth 1st Quarter- Division and Corporate Holdings Update
10. Adeptia Announces 75% Revenue Increase for 2012 Calendar Year
11. Ekahau Achieves 45% Year-over-Year Revenue Growth and Strong Adoption of Safety Alert Solution in 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... report its first quarter 2015 results before the Nasdaq ... then host a live conference call and webcast to discuss ... morning, April 30, 2015 at 8:00 a.m. Eastern Time ... the live conference call by dialing 866-952-1906 (US) or ...
(Date:4/23/2015)... FRANCISCO, Calif. , April 23, 2015  Veracyte, Inc. ... entered into a definitive agreement to sell approximately $40 ... Under the agreement, the investors will purchase an aggregate ... price of $8.15 per share, the closing stock price ... by new and existing investors, including Broadfin Capital, Camber ...
(Date:4/23/2015)... HOUSTON , April 23, 2015  Metanome, ... today announced the company has changed its name ... reflect Diversigen,s positioning as the single commercial source ... need to capitalize on the diverse opportunities of ... types that Diversigen accepts – including those that ...
(Date:4/23/2015)... Delpor, Inc. (Delpor), a biotechnology company ... States Patent and Trademark Office has issued 2 new ... US Pat. No. 8,986,727 was issued on March ... device for the sustained release of therapeutic agents. ... sustained (zero-order) release of large and small molecules for ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... June 2 NeoGenomics, Inc. (OTC Bulletin ... Sixth Annual Noble Financial Equity Conference at 12:30 PM ... the Seminole Hard Rock Hotel in Hollywood, FL. ... give a presentation regarding NeoGenomics, market positioning, financial performance, and ...
... Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company,s participation at two ... , , EVP ... SMID Cap Conference at the InterContinental Hotel in Boston, Mass. beginning at ... , , ...
... to be effective in making silicon-based electronics may be viable ... molecule thick. Researchers at the Max Plank Institute for Metals ... online in the journal Physical Review B on June 1. ... the basis for a host of extremely small and efficient ...
Cached Biology Technology:NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 2NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 3Genoptix Announces Participation at June Investor Conferences 2
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... that have died in mass strandings in New Zealand ... a new study concludes, challenging a popular assumption that ... almost certain death because of familial ties. Using ... determined that both related and unrelated individuals were scattered ...
... , Francisella tularensis , the cause of tularemia ... considered a potential biological weapon because it is readily aerosolized ... humans. While a live attenuated vaccine strain has been ... understand the basis for its attenuated virulence. In an ...
... engineers are developing the right mix to reduce concrete,s ... biofuel byproducts. "The idea is to use bioethanol ... concrete as a partial replacement of cement," said Feraidon ... using these materials we can reduce the carbon footprint ...
Cached Biology News:Study questions the role of kinship in mass strandings of pilot whales 2Study questions the role of kinship in mass strandings of pilot whales 3News tips from the journal mBio®, volume 4, issue 1 2Researchers building stronger, greener concrete with biofuel byproducts 2Researchers building stronger, greener concrete with biofuel byproducts 3
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Biology Products: